Rosiglitazone inhibits adrenocortical cancer cell proliferation by interfering with the IGF-IR intracellular signaling.

Rosiglitazone inhibits adrenocortical cancer cell proliferation by interfering with the IGF-IR intracellular signaling.
复制标题

罗格列酮通过干扰IGF-IR细胞内信号传导来抑制肾上腺皮质癌细胞的增殖。

DOI:
10.1155/2008/904041
复制
发表时间:
2008
期刊:
影响因子:
2.9
通讯作者:
Luconi, Michaela
Luconi, Michaela
中科院分区:
医学3区
文献类型:
--
作者:
Cantini, Giulia;Lombardi, Adriana;Piscitelli, Elisabetta;Poli, Giada;Ceni, Elisabetta;Marchiani, Sara;Ercolino, Tonino;Galli, Andrea;Serio, Mario;Mannelli, Massimo;Luconi, Michaela

文献摘要

参考文献

被引文献

相似文献

罗格列酮(RGZ)是一种过氧化物酶体增殖激活受体(PPAR)-γ的噻唑烷二酮配体,最近被描述为具有抗肿瘤特性。我们研究了RGZ对人肾上腺皮质癌(ACC)两种细胞系模型(SW13和H295R)细胞增殖的影响及其与激活的IGF-I受体(IGF-IR)信号通路的相互作用。我们证实了IGF-IR在两种细胞系和ACC中的高表达。igf - 1以剂量和时间依赖的方式刺激细胞增殖,而RGZ则抑制细胞增殖。通过分析活化的IGF-IR下游的主要细胞内信号通路、磷脂酰肌醇3-激酶(PI3K)-Akt和细胞外信号调节激酶(ERK1/2)级联,我们发现RGZ可以快速干扰Akt和ERK1/2的磷酸化/活化,从而介导IGF-I刺激的增殖。综上所述,我们的研究结果表明,RGZ通过干扰激活IGF-IR下游的PI3K/Akt和ERK1/2信号通路,对人ACC细胞增殖具有抑制作用。
Rosiglitazone (RGZ), a thiazolidinedione ligand of the peroxisome proliferator-activated receptor (PPAR)-γ, has been recently described as possessing antitumoral properties. We investigated RGZ effect on cell proliferation in two cell line models (SW13 and H295R) of human adrenocortical carcinoma (ACC) and its interaction with the signaling pathways of the activated IGF-I receptor (IGF-IR). We demonstrate a high expression of IGF-IR in the two cell lines and in ACC. Cell proliferation is stimulated by IGF-I in a dose- and time-dependent manner and is inhibited by RGZ. The analysis of the main intracellular signaling pathways downstream of the activated IGF-IR, phosphatidyl inositol 3-kinase (PI3K)-Akt, and extracellular signal-regulated kinase (ERK1/2) cascades reveals that RGZ rapidly interferes with the Akt and ERK1/2 phosphorylation/activation which mediates IGF-I stimulated proliferation. In conclusion, our results suggest that RGZ exerts an inhibitory effect on human ACC cell proliferation by interfering with the PI3K/Akt and ERK1/2 signaling pathways downstream of the activated IGF-IR.
DOI: 10.1161/atvbaha.107.160713
发表时间: 2008-04-01
影响因子: 8.7
作者:
Lombardi, Adriana;Cantini, Giulia;Luconi, Michaela
通讯作者: Luconi, Michaela
DOI: 10.1530/eje.1.02116
发表时间: 2006-04-01
影响因子: 5.8
作者:
Slater, EP;Diehl, SM;Bartsch, DK
通讯作者: Bartsch, DK
DOI: 10.1210/jc.2004-1267
发表时间: 2005-07-01
影响因子: 5.8
作者:
Betz, MJ;Shapiro, I;Beuschlein, F
通讯作者: Beuschlein, F
DOI: 10.1158/0008-5472.can-05-3111
发表时间: 2006-02-01
期刊: CANCER RESEARCH
影响因子: 11.2
作者:
He, GB;Sung, YM;Fischer, SM
通讯作者: Fischer, SM
DOI: 10.1124/mol.106.028902
发表时间: 2007-03-01
影响因子: 3.6
作者:
Kempna, Petra;Hofer, Gaby;Flueck, Christa E.
通讯作者: Flueck, Christa E.